Skip to main content

Table 2 Cost-effectiveness and -benefit for the base case

From: Cost-effectiveness of the recommended medical intervention for the treatment of dysmenorrhea and endometriosis in Japan

Group Expected cost (JPY) Expected effectiveness (QALYs)
(a) The base case from the perspective of healthcare payers
 Guideline-based interventiona 326,806 14.9
 Self-carea 27,758 12.3
 Incremental 299,048 2.6
Group Total costb (JPY)  
(b) The base case from the societal perspective
 Guideline-based intervention 1,643,076  
 Self-careb 4,768,899  
 Societal monetary value (SMV) Δ3,125,823  
  1. The incremental cost-effectiveness ratio (ICER) was approximately 115 thousand JPY ($958) per quality-adjusted life-year (QALY) gained, retrospectively. Thus, the model simulation revealed that early physician consultation and guideline-based intervention would be more cost-effective than self-care, as the aforementioned ICER is below the willingness to pay (WTP) threshold
  2. In the cost–benefit analysis, the aforementioned SMV favored early physician consultation and guideline-based intervention
  3. a Medical direct costs, which were established from the National Health Insurance scheme, consist of outpatient visits (inclusive of drugs), inpatient care, and surgery
  4. b Total costs consist of medical direct, non-medical and opportunity costs